Understanding how a specific immune cell contributes to rheumatoid arthritis
Defining the Pathogenic Contribution of High Genotypic MIF Expression
This study is looking at a special type of immune cell that might play a big role in how rheumatoid arthritis gets worse, and by understanding how these cells work, we hope to find new ways to help people with this condition feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11077285 on NIH RePORTER |
What this research studies
This research investigates the role of a unique T cell population that expresses the macrophage migration inhibitory factor (MIF) receptor in the progression of rheumatoid arthritis (RA). By studying how these cells contribute to inflammation and joint destruction, the research aims to uncover new mechanisms of disease persistence. The approach includes characterizing the signaling pathways and responses of these T cells in both mouse models and human samples. This could lead to better understanding and potential new treatments for RA.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with rheumatoid arthritis, particularly those experiencing severe symptoms or disease progression.
Not a fit: Patients with rheumatoid arthritis who are in remission or have mild symptoms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to novel therapeutic strategies that target specific immune responses in rheumatoid arthritis, potentially improving patient outcomes.
How similar studies have performed: Other research has shown promise in targeting immune cell populations in autoimmune diseases, suggesting that this approach could yield significant insights.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Bucala, Richard J — Yale University
- Study coordinator: Bucala, Richard J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.